M1 KLINIKEN AG O.N.
Commented by Lars Winter on September 29th, 2026 | 08:00 CEST
Drone Contract for Volatus, AI Power Drives Infineon and a Beauty Boom at M1 Kliniken: Three Exciting Stocks Under the Microscope
Drones for the Canadian military, chips for the AI boom, and beauty treatments with hefty margins: Stock market excitement comes in many forms. Volatus Aerospace could be on the verge of a growth spurt thanks to a Canadian military contract. Infineon is benefiting from data centres' insatiable appetite for power, while M1 Kliniken is ramping up its beauty business. Three different stories with one thing in common: operational progress could translate into further share price gains. We take a closer look at these three exciting stocks in our stock analysis.
Read
Commented by Mario Hose on January 30th, 2020 | 07:34 CET
After M1 now CR Capital with price jump: When does MPH share react?
The holding company MPH Health Care AG can be pleased about the positive development of its investments. After the share price of M1 Klinken AG had increased significantly in recent weeks, driven among other things by positive analyst comments and the successful international expansion, the share of CR Capital Real Estate AG yesterday rose by 12.4% to EUR 36.20. The MPH share should also benefit from this development. The value of the M1 participation alone meanwhile exceeds the total market capitalisation of MPH of EUR 178 million. Thus, investors will receive the 50-percent shareholdings in CR Capital and Haemato AG with a combined market value of EUR 100 million free of charge. When does the MPH share react?
Read
Commented by Mario Hose on January 23rd, 2020 | 05:50 CET
Berenberg says "buy": Next recommendation for MPH investment M1 Kliniken AG
The analysts at Berenberg have begun coverage of M1 Klinken AG and have recommended the share as a buy. With more than 70 doctors and over 200,000 treatments annually, M1 is the market leader for beauty medicine in Germany. Thanks to its strategy "highest quality at the best price", the company has been able to achieve annual growth rates of around 30% since 2014. The investment of MPH Health Care, which is also listed on the stock exchange, should also grow significantly in the future. The driving forces are the increasing market penetration in Germany and the international rollout. The analysts expect EBIT to grow by 30% annually until 2022 and recommend buying the M1 share with a price target of EUR 18. Analysts from Commerzbank, Kempler or GBC also recommend buying.
Read
Commented by Mario Hose on January 15th, 2020 | 07:42 CET
Fresenius Peer: Will the analysts' favorite M1 Kliniken 2020 take off?
Besides Fresenius, M1 Klinken AG is one of the few listed clinic operators in Germany. Unlike the clinic group, M1 has specialised in a lucrative niche: the beauty market. More and more people are helping with beauty and are generating billions in sales in the industry. In just a few years, M1 has become the market leader for beauty medicine in Germany. A growth rate of 30% is also targeted for the future. Foreign business is increasingly becoming the growth driver. After a continuous price increase between 2016 and 2018, the share has consolidated in 2019. But operationally things are still running smoothly. Analysts see more than 50% upside potential.
Read
Commented by Mario Hose on November 25th, 2019 | 05:54 CET
MPH Health Care investment HAEMATO with growth in Q3 - shares before turnaround?
HAEMATO AG, a provider of special pharmaceuticals and a subsidiary of MPH Health Care, which is also listed on the stock exchange, returned to growth in the third quarter of 2019. The company is also continuing to optimize its business processes and approve new products in order to broaden its portfolio. This means that the stocks could also face a turnaround. Analysts also see significant price potential.
Read